3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
87
Colorectal Neoplasms
82
Stomach Neoplasms
59
Pancreatic Neoplasms
56
Carcinoma, Non-Small-Cell Lung
46
Melanoma
34
Carcinoma, Renal Cell
29
Neoplasm Metastasis
25
Neoplasms
24
Esophageal Neoplasms
24
Colonic Neoplasms
22
Squamous Cell Carcinoma of Head and Neck
21
Carcinoma, Transitional Cell
20
Liver Neoplasms
19
Ovarian Neoplasms
17
Adenocarcinoma Of Esophagus
17
Esophageal Squamous Cell Carcinoma
16
Triple Negative Breast Neoplasms
15
Rectal Neoplasms
15
Breast Neoplasms
14
Biliary Tract Neoplasms
14
Uterine Cervical Neoplasms
13
Lung Neoplasms
12
Cholangiocarcinoma
12
Carcinoma, Merkel Cell
12
Head and Neck Neoplasms
10
Prostatic Neoplasms
9
Gastrointestinal Neoplasms
9
Small Cell Lung Carcinoma
8
Endometrial Neoplasms
8
Interventions
apatinib
9
Paclitaxel
9
Capecitabine
7
Oxaliplatin
6
camrelizumab
5
Cisplatin
5
S 1 (combination)
4
Fluorouracil
3
Docetaxel
3
130-nm albumin-bound paclitaxel
3
titanium silicide
2
Leucovorin
2
Drug Therapy
2
vorolanib
1
trifluridine tipiracil drug combination
1
tipiracil
1
spartalizumab
1
rucaparib
1
relatlimab
1
raltitrexed
1
pazopanib
1
olaparib
1
lobaplatin
1
linrodostat
1
ezogabine
1
endostar protein
1
durvalumab
1
dacomitinib
1
capivasertib
1
Trifluridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Gastric Cancer
×
Nivolumab
×
Gastrointestinal
×
Clear all
NCT02935634
2023-06-09
FRACTION-GC
Bristol-Myers Squibb
Phase 2
Completed
190 enrolled
25 charts